Curated News
By: NewsRamp Editorial Staff
April 11, 2025
Nutriband Receives Patent for AVERSA Abuse-Deterrent Transdermal Technology in Macao
TLDR
- Nutriband (NASDAQ: NTRB) granted patent in Macao for AVERSA abuse-deterrent transdermal technology, enhancing global IP portfolio.
- AVERSA technology reduces abuse, diversion, and accidental exposure of transdermal drugs, incorporating abuse-deterrent fentanyl patch for commercialization.
- Nutriband's AVERSA technology aims to make the world safer by preventing abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
- Nutriband's AVERSA Fentanyl patch with abuse-deterrent technology is on track to be the world's first, projecting substantial U.S. sales.
Impact - Why it Matters
This news matters as it highlights Nutriband's innovative efforts to address the abuse and misuse of transdermal drugs like opioids. The development of AVERSA technology has the potential to significantly impact the pharmaceutical industry by providing a solution to prevent abuse, diversion, and accidental exposure of drugs with abuse potential, ultimately contributing to public health and safety.
Summary
Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, has been granted a patent in Macao for its AVERSA abuse-deterrent transdermal technology. The patent adds to Nutriband’s global IP portfolio, with coverage now spanning 46 countries. AVERSA is designed to reduce abuse, diversion, and accidental exposure of transdermal drugs like opioids, with Nutriband aiming to commercialize the world’s first abuse-deterrent fentanyl patch.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Nutriband Receives Patent for AVERSA Abuse-Deterrent Transdermal Technology in Macao
